Abstract | Post-transplant lymphoproliferative diseases (PTLD) associated with Epstein-Barr virus (EBV) infection often develop after organ and haematopoietic stem-cell transplantation. These lymphoproliferative diseases are tumours that usually express all latent EBV viral proteins, and are therefore amenable to T-cellbased immune therapies, such as donor lymphocyte infusions and the adoptive transfer of EBV-specific cytotoxic T lymphocytes. In this Review, we describe current approaches of T-cell-based therapies to treat PTLD, and describe strategies that improve the feasibility of such treatment.
Introduction
Epstein-Barr virus (EBV)-associated lympho proliferative disease occurring after haematopoietic stem-cell transplantation or solid organ transplantation is a potentially life-threatening condition.
1,2 The ability of EBV to persist and become reactivated in B cells is a unique characteristic of gamma herpesviruses and is fundamental to the pathogenesis of post-transplant lymphoproliferative diseases (PTLD), which occur when the T-cell immune response to EBV is ablated or severely compromised by immunosupression.
3 Despite the availability of therapies that target EBV-infected B cells, PTLD can occur rapidly and is potentially lethal. 1 An attractive strategy for the treatment and prevention of this devastating complication is based on the use of ex vivo-derived EBV-specific cytotoxic T lymphocytes (EBV-CTL) to reconstitute the immune response to EBV, 1, 4 and several studies have confirmed the promise of this strategy. [5] [6] [7] The rationale for exploring T-cell therapy for this disease is to restore the underlying immune defect, which leads to the development of PTLD without causing bystander organ toxi city and/or further immune suppression. In this article we discuss EBV biology and the pathogenesis of PTLD to emphasise the importance of the cell-mediated immune response for the control of this disease. We then discuss the advances in T-cell-based therapies for PTLD, including the advantages and disadvantages of each approach. Finally, we highlight the key strategies that are currently being used to broaden the application of this therapy beyond single centres.
Epstein-Barr virus
EBV is a ubiquitous human herpesvirus that enters its human host via a mucosal route, infects and replicates in oropharyngeal epithelial cells and then infects B lymphocytes in the oropharynx (Figure 1) . 8 Infected B cells do not produce infectious virus, but instead express viral latency-associated proteins that induce B-cell proliferation and then drive the infected B cell into 'true latency' , in which no viral genes are expressed. 9 These infected B cells are phenotypically indistinguishable from normal memory B cells and are 'invisible' to the immune response and, therefore, persist long term. 8, 10 The virus life cycle is completed when infected B cells circulate through the oropharynx, where the virus reactivates from latency, and infectious virus is released into the saliva to infect new hosts. 10 The transition from newly infected B cell to infected memory B cell carrying virus in 'true latency' involves three stages of 'transitional' latency and each latency type is associated with specific B-cell malignancies (Box 1). 8, 10 Virus replication is important for virus transmission and to maintain the pool of infected memory B cells. 10 The role of the lytic cycle in established PTLD is minimal, and drugs, such as acyclovir, that inhibit viral replication have no impact on established tumours. 11 However, viral replication and spread seem to be important for transmission of the virus from infected donor B cells in an organ graft to recipient B cells.
12 This is evident in seronegative transplant recipients who become infected with EBV from seropositive donors. Recipients of intestinal grafts carrying a high B-cell load are at particularly high risk for PTLD, and this situation can be ameliorated by pre-emptive use of replication cycle inhibitors during the peritransplant period. 12 
Pathobiology and presentation of PTLD
The normal balance between latently infected B cells and the EBV-specific T cells, from either the donor or the recipient can be disrupted as a consequence of the immuno compromised state of patients after transplantation of solid organs or haematopoietic stem cells. This imbalance results in an increase of latently infected B cells, which may develop into PTLD. 13 This serious, and often life-threatening, disease is characterized by four major histological subtypes (early lesions, monomorphic, polymorphic, and classic Hodgkin lymphoma-type), 14 which are all associated with EBV infection. Symptoms and signs of PTLD can include fever, lymphadenopathy, fulminant sepsis, and mass lesions in the lymph nodes, spleen, or central nervous system. 1 It can also present as a lymphomatous growth within the transplanted organ (for instance, small intestine, lung, liver or kidney). 1 PTLD after HSCT PTLD developing after haematopoietic stem-cell transplantation (HSCT) usually results from donor B cells and appears within the first 6-12 months of the posttransplant period, when profound deficiencies of EBVspecific CTL are seen. 15 However, in the setting of reduced-intensity conditioning regimens that include anti thymocyte globulin (ATG) or alemtuzumab, some centres have described a high incidence of PTLD involving B cells from recipient paediatric patients.
16,17 Risk factors for the development of PTLD include the use of a donor stem-cell product depleted of T cells, a high degree of HLA-mismatch between donor and recipient, the degree and duration of immunosuppressive treatment after the transplant, and the use of ATG with reducedintensity transplant conditioning.
18 After HSCT, PTLD may present with a clinical picture similar to infectious mononucleosis with B symptoms (fevers, sweats, anorexia) and tonsilar enlargement and cervical lymphadenopathy. In highly immunosuppressed patients, the clinical presentation may also be more fulminant with diffuse multiorgan involvement and a clinical picture that is similar to sepsis or graft-versus-host disease (GvHD).
PTLD after solid organ transplant
Patients undergoing solid organ transplantation most commonly develop PTLD exhibiting type III latency in the first year, with the disease often arising from lymphoid cells of their own haematopoietic system (Box 1).
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The incidence can vary from 1% to 30% depending on the type of organ transplanted. The risk factors for this form of the disease include both the inability to develop an immune response against primary infection because of the EBV-seronegative status of the recipient prior to transplantation, and a higher dose of immuno suppressive treatment after receiving organs with more lymphoid tissue, such as small intestine or lung. Hence, children are particularly susceptible to PTLD, because they are more often EBV-seronegative at the time of transplantation.
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PTLD can be categorized into 'early' or 'late' lymphoma depending on the interval of its development after transplantation. 21 This classification is closely linked to the intensity of immunosuppression occurring in the first period post-transplantation. Early PTLD develops within the first year after transplantation and is invariably associated with EBV. By contrast, the so-called 'late' form, develops 2-5 years or more after transplantation and its patho genesis is probably multi-factorial with a significant number of cases being EBV-negative. 22 These late-onset lymphomas also have a much poorer prognosis than their earlier counterparts and require more-aggressive therapies. After transplantation of solid organs or haemato poietic stem cells, EBV viral load in peripheral blood should be monitored in patients at high risk of developing PTLD, according to published guidelines; [23] [24] [25] if tracked over time, this sensitive-though non-specific-laboratory value can indicate likely viral reactivation.
Treatment of PTLD
Whether the intent is to prevent or to treat EBV-associated PTLD arising after solid organ transplantation and HSCT, the two approaches used are to remove the infected B cells, and restore and expand an EBV-specific T-cellmediated immune response. Several guidelines and algorithms for the sequential application of these strategies in patients with PTLD have been published. 23, [26] [27] [28] [29] In the setting of solid organ transplantation, these guidelines suggest initial reduction of immune suppression if possible. If this manoeuvre is unsuccessful, second-line therapies include rituximab-a chimeric murine/human monoclonal antibody against CD20, an antigen expressed in the surface of B-cells-either alone or in combination with chemo therapy such as CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) in patients with more-extensive or rapidly progressive disease. 23, 29 Toxicity associated with chemotherapy is a concern in patients with co-morbidities and for this reason less-intensive regimens are often used, particularly in children. 20, 29 After HSCT, reduction in immune suppression rarely results in sufficient recovery of EBV-specific immunity to eradicate PTLD. Rituximab has proved effective both as pre-emptive therapy in patients with high EBV viral loads and as treatment for patients with established PTLD, producing response rates of 55-100% in both scenarios. [30] [31] [32] Nevertheless, PTLD often recurs because cellular immunity against EBV has not been restored. 33 Rituximab also increases the risk of infection in a population that is already immunosuppressed and can be ineffective as some tumours do not express CD20. Thus, strat egies to restore immunity by infusing T cells that target EBV antigens have been developed and are being used by several groups, often after failure of immunotherapy reduction and rituximab. Because many PTLDs express type III latency, this setting serves as a good model for testing T-cell-based therapies designed to target EBV antigens that are presented on the cell surface by major histocompatibility molecules.
T-cell therapy for PTLD
Understanding the latency states of EBV is important for the appropriate design of immunotherapies that target viral antigens for the eradication of tumour cells. EBV-transformed B-lymphoblastoid cell lines (LCLs) are ideal antigen-presenting cells (APCs) for the activation of T cells used in immunotherapy for type III malignancies because they express the same 10 viral antigens. They also express high levels of class I/class II HLA and co-stimulatory molecules, are readily generated from healthy donors, and grow to large numbers.
3 EBV-specific CTLs are also easily activated from healthy EBV-seropositive HSCT donors using LCLs as APCs, and have been effective in recipients. 1 In solid organ recipients, in vivo T-cell expansion is compromised by the continued immunosuppression required by these patients. Nevertheless, EBV-specific T cells can be expanded from patients ex vivo, and have been used with some success. [34] [35] [36] For patients with late PTLD expressing type II latency, T cells must be focused on the three viral proteins expressed-latent membrane proteins 1 and 2 (LMP1 and LMP2), and Epstein-Barr virus nuclear antigen (EBNA1)-so LCLs that express all 10 latency proteins are not ideal APCs. However, monocytes and LCLs expressing LMP1 and LMP2 from adenoviral vectors can reactivate LMP-specific T cells that are effective for the treatment of type II latency tumours. 37 Since EBNA1 is poorly immunogenic, there has so far been little clinical experience in targeting type I latency tumours (Burkitt's lymphoma) with T cells. 38 
Donor unmanipulated lymphocyte infusions
Because most HSCT donors are EBV seropositive, EBVspecific T-cell response can be increased in patients who develop PTLD in the allogeneic transplant setting by infusing unmanipulated donor lymphocytes. 39, 40 This strategy has shown efficacy in more than 70% of patients with PTLD after HSCT. 6 However, this strategy is associated with an increased incidence of severe or fatal GvHD, due to the presence of alloreactive T cells in the infused cell product. 39, 40 This problem could potentially be overcome by genetically modifying the T cells with a suicide gene, such as the herpes simplex virus-derived thymidine kinase (TK) gene. If GvHD were to occur, T cells transduced with this gene can then be killed by infusion of ganciclovir. This approach has shown efficacy in early phase studies and is currently being evaluated in a phase III licensing trial in Europe. 41 Nonetheless, concerns with this approach include the development of an immune response against the xenogeneic thymi dine 
BL, gastric cancer kinase (TK) antigen and the removal of ganci clovir as an option for treating viral infections, such as cytomegalovirus (CMV) after transplantation. These considerations have generated interest in using alternative suicide genes, such as inducible human caspase 9. 42 Donor EBV-specific CTLs in HSCT recipients An alternative approach to reducing alloreactivity of donor T cells is to selectively expand T-cell lines directed against EBV antigens, using EBV-LCLs that, similar to PTLDs, express type III latency (Figure 2) . Such T-cell lines usually contain both CD4 + and CD8 + T cells that recognize multiple latent and early lytic cycle viral antigens and, when infused into patients, can reconstitute an immune response to EBV and eliminate PTLD without inducing GvHD. Our group recently completed studies in 114 patients who received EBV-specific CTLs to prevent or treat PTLD at three institutions (Table 1) . 5 No patients developed de novo GvHD after CTL infusion, and the most significant adverse effect was localized, but reversible, swelling at sites of disease during the therapeutic response in four patients with active disease.
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Among all patients, 101 received CTL infusions as prophylaxis resulting in up to a four-log expansion of infused CTLs. None of these patients developed PTLD. Of the 13 patients who were treated for active disease, 11 patients achieved complete remissions that were sustained without recurrence. One patient died very early after treatment of progressive disease and a second patient did not respond because her tumour had a deletion of the two epitopes in the EBNA3B recog nized by the infused line. 44 The first 26 patients of the 114 patients received cells that had been genetically modified with a retroviral vector encoding the neo mycin resis tance gene as a marker, which allowed us to track the infused T-cells for up to 9 years. 5 We concluded from this study that treatment with adoptively transferred donor-derived EBV-specific CTLs is a safe and effective prophylactic approach or treatment method for PTLD, and that the manufacturing methodology is robust and reproducible, and can be used in other institutions.
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A second large study was recently reported by researchers based at the Memorial Sloan-Kettering Cancer Center and led by Richard J. O'Reilly. Their results in 47 patients with EBV-PTLD treated with donor lymphocyte infusions (DLI), donor derived EBV-CTLs or third party EBV-CTLs showed an overall response rate of 68% without evidence of de novo or recurrent GvHD.
6 Analysis in vitro of the cases of patients who did not respond to CTL therapy showed three cases in which the CTL generated from the donor-by using donor LCLs transformed with EBV-producing marmoset B-cell line (B95-8)-did not lyse LCLs expanded from the patient's blood or biopsied tumour. By contrast, CTL generated using LCL lines transformed with the patients own strain of EBV derived from the recipient could lyse LCLs from either the recipient or the donor. In another case, in which donor and recipient were a 7/10 match and the recipient had not responded to CTL therapy, the PTLD was proved to be of recipient origin, and the infused cell line was selectively restricted by HLA*A1101, present only in the donor. This patient subsequently received a partially HLA-matched third-party EBV-CTL line that had significant activity restricted by an HLA allele expressed by the patient's tumour and achieved a complete response. Together, these cases, and those observed by our group, 44 suggest that a lack of response to CTL therapies may reflect an infused line with a restricted specificity or antigenic differences between the EBV strain causing the PTLD and the B95-8 strain. Use of EBV-CTL lines from another donor should be considered in this situation. Several other smaller studies (Table 1) show response rates similar to those obtained by the Baylor 44 and Memorial Sloan-Kettering groups.
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Autologous EBV-CTLs in solid organ recipients Are the successes with EBV CTLs in HSCT recipients reproducible in recipients of solid organ transplantation? In this setting, PTLD most commonly arises from recipient B cells and the donor is often not accessible. Moreover, because the donor and recipient are rarely HLA-matched, donor-derived T cells would need to have activity through shared antigens to be effective. Although patients usually remain on long-term immuno suppression, several groups have successfully generated recipient CTLs and tested them for activity in vivo (Table 2) . Our group has administered autologous EBV-specific CTLs to 10 patients with persistently high or rising EBV DNA levels after solid organ transplantation. 36 Although the CTL infusions failed to decrease the viral load in a consistent manner, none of the patients developed PTLD. Treatment of two patients with active disease yielded a complete response and a partial response that persisted for up to 1 year. 36 This experience is consis tent with reports of other investigators
3 Three of these are found in post-transplant lymphoproliferative diseases (PTLD) and each is associated with a different type of virus-gene expression, different levels of immunogenicity, and different types of lymphoma.
11 In type III latency, the virus expresses all 10 of its latency-associated proteins that together induce B-cell transformation.
1 Tumours expressing type III latency are invariably of B-cell origin and develop early after transplant, during the period of most-intense immune suppression. In recipients of solid organ transplants (SOT), B cells expressing type III latency are frequently detected in lymph nodes and may be categorized as lymphoid hyperplasias that may never develop into full-blown lymphoma and that frequently respond to reduced immune suppression. However, they may develop into diffuse large B-cell lymphomas (DLBCLs) in both SOT and haematopoietic stem-cell transplantation (HSCT) recipients.
1 These lymphomas are highly immunogenic, generally susceptible to EBV-specific T-cell therapy and are never seen in immunocompetent individuals. Late after SOT, patients are susceptible to the less immunogenic type I and type II latency tumours that require additional oncogenic events to compensate for their reduced viral-gene expression and can also arise in immunocompetent individuals. 1 Burkitt's lymphoma expresses type I latency viral genes-EB nuclear antigen 1 (EBNA1) and latent membrane protein 2 (LMP2)-and is poorly susceptible to the immune response. Hodgkin lymphomas and non-Hodgkin lymphomas express type II latency (EBNA1, LMP1 and LMP2) and have intermediate immunogenicity. In the fourth type of latency, type 0 latency, no viral genes are expressed. Type 0 latency is not detected in tumours, as EBNA1 is required for the maintenance of the viral genome.
who have used similar preparations to treat patients with elevated EBV viral load or active disease (Table 2) . 34, 35, 45 Overall, these studies have helped to allay concerns that autologous EBV-specific CTL might induce rejection of the transplanted solid organ. 35, 36 This progress notwithstanding, the expansion and persistence of the CTLs were less than observed after HSCT, likely because of the need to continue immunosuppressive treatment for patients after solid organ transplantation and because the lympho depletion associated with HSCT is highly conducive to in vivo T-cell expansion. 46 The type I and II latency malig nancies that occur years after solid organ transplantation are less immunogenic and more immuno suppressive than classic PTLDs, and may require T cells that are genetically modified to resist immunosuppressive molecules 47 and/or immunosuppressive drugs. Combination therapies with drugs that modify the tumour environment may also be beneficial but will likely be evaluated first outside of the transplant setting.
Simplifying the use of EBV-CTLs
In general, the manufacturing process of EBV-CTLs takes approximately 8-12 weeks, and half of this time is required for the generation of the APCs (EBV-LCL). The other half of the time is required for the generation and expansion of the EBV-specific CTL to obtain the cell numbers that are required for clinical use as well as product testing. 48 The widespread use of T cells to prevent or treat EBV-PTLD is limited by this relatively long production time, as they cannot be generated in response to a patient developing PTLD. However, several groups have explored the development of more-rapid approaches for the production of virus-specific T cells. [49] [50] [51] [52] [53] [54] Three such methods have been used clinically; 51, 55, 56 firstly, multimer selection, which selects T cells directed against specific viral peptides in the context of a specific HLA class I molecule; secondly, IFN-γ capture, in which cells responding to stimulation by viral antigens are selected on the basis of their secretion of IFN-γ; and lastly, faster CTL culture methods that use peptides or plasmid-derived viral antigens expressed in dendritic cells to stimulate T-cells in the presence of cytokines. These strategies essentially enable the enrichment of virus-specific CTL derived from a small star ting population of antigen-specific T cells. Despite the small numbers of T cells infused using this approach, the highly specific T-cell populations have the potential to expand exponentially in vivo when they encounter antigen, thereby providing potent antiviral activity.
Rapid ex vivo culture
To reduce the time to manufacture and develop a strategy that avoids the use of live viruses in APC, Gerdemann et al., 57 have developed an approach to generate virusspecific T cells (rCTL). This method consists of a single stimulation of T cells with dendritic cells previously transfected (using nucleofection) with DNA plasmids encoding immunogenic EBV (LMP2, EBNA1 and BZLF1), as well as antigens from adenovirus and CMV, and later expansion of the stimulated cells in the presence of interleukin (IL)-4 and IL-7 in a gas permeable culture device, which is used to promote gas exchange, improve the nutrient supply and prevent waste accumulation in the T-cell cultures. In preliminary results 'rapidCTLs' have been able to control infections inclu ding EBV-PTLD with no GvHD. 58 Virus-derived peptides can also produce rapid T-cell expansion from peri pheral blood mononuclear cells in the presence of cytokines and further reduce the culture time by eliminating the requirement for dendritic cells. 59 However, this approach has yet to be tested clinically.
Tetramer selection
Cobbold and colleagues 54 were the first to report the use of tetrameric HLA-peptide constructs (tetramers) to select a virus-specific T-cell population for clinical use. This group infused patients with CMV peptide-specific CD8 + T cells isolated directly from the donor's peri pheral blood by incubating these cells with tetramers, followed by selection of T cells bound to the tetramers with magnetic beads. 54 They were able to detect CMV-specific T-cell function in the patient within 10 days of infusion despite the small number of virus-specific CD8 + cells infused. In a subsequent study, Schmitt and co-workers 60 exploited a novel streptamer technology to select CMVspecific T cells for transfer into patients with recurrent high CMV antigenemia after HSCT. This technique combines the tetramer isolation approach with Strep-tag®-Strep-Tactin® technology, which results in a reversibility of the TCR-major histocompatibility complex (MHC) inter action and enables more-effective purification of antigen-specific T cells without affecting their functional state. They reported a dramatic expansion of CMVspecific CD8 + effector T cells in associ ation with clearance of CMV antigenemia. 60 An additional case illustrates how this approach can be applied to EBV. 56 Tetramers were used to select T cells specific for two EBV antigens recognized in the context of HLA A2 from a haploidentical parent donor. 60 A small dose of 10 4 CTLs/kg was infused into the recipient, who shared HLA A2 and had developed PTLD after a cord blood transplant. A dramatic expansion of T cells coincided with a clinical response. A second infusion, administered in response to a probable early relapse (development of fever and recurrent detection of EBV in blood and tonsils) at 12 months post transplantation, also induced a response. Although these results are encouraging, the restricted specifi city could result in tumour evasion, and such a strategy is limited to donors who express HLA alleles for which viral peptides are available, and for which sufficient circulating T cells specific for the peptide can be isolated from the donor.
Isolation of IFN-γ secreting T cells Selection of T cells that secrete IFN-γ in response to
antigen provides an alternative strategy for the immediate isolation of populations of virus-specific T cells. Moosmann and colleagues 51 used immunomagnetic separation to select cells that secreted IFN-γ in response to stimulation of donor mononuclear cells with 23 class I and II peptides derived from 11 EBV antigens. Six patients with PTLD-three of them with early stage disease-who received an average dose of 4 × 10 6 selected T cells had complete responses, whereas three patients with more-advanced disease did not respond to the treatment. 51 This finding raises important issues. First, will CTLs that target selected EBV-peptides be as effective as CTLs activated using LCLs? Notably, CTLs activated with LCL antigens are physiologically processed, ensuring that the generation of CTL lines have high-avidity CTLs with broad reactivity against multiple CD4 and CD8 epitopes. An alternative approach is to use overlapping peptide pools from selected EBV antigens (for example, EBNA1). Second, which EBV antigens will induce protective T cells? We have elected to use three EBV antigens: latent LMP2, which is subdominant, but recognized by a majority of donors and expressed in type II and type III latencies; EBNA1, which elicits CD4 + T cells in a majority of donors and is expressed in all EBV-associated malignancies; and BZLF1, which is an immunodominant lytic cycle protein. 61 This combination has proved effective in preliminary clinical studies. 58 Another concern regarding the attempts to broaden antigenic coverage is that it may increase competition for peptide binding to HLA, or generate EBV-specific T cells with cross-reactivity against alloantigens. 62, 63 However, de novo alloreactivity was not observed among 153 recipients who received CTLs generated using LCL as stimulator cells-including 73 patients for whom there was an HLA mismatch with the donor-and competition for HLA molecules did not reduce the repertoire of expanded T cells in our preliminary studies. 64 Strategies for direct selection of EBVspecific T cells from peripheral blood require large blood volumes or apheresis products, which would be feasible only for related donors. 56 Third party EBV-CTLs EBV CTLs could be made rapidly available to a larger number of patients if there was a bank of characterized HLA-typed EBV-specific T-cell lines. This third-party approach was first tested in the clinic by Haque and colleagues, 65 who manufactured a bank of polyclonal EBV CTL lines for the treatment of EBV-associated diseases in patients undergoing HSCT or solid organ transplantation. Eight patients with PTLD received closely HLA-matched EBV-specific CTL. The CTL lines were generated from unrelated third-party blood donors and selection of the CTL were based primarily on the best HLA match. 66 Using this approach, three patients attained a complete remission without evidence of alloreactivity (Table 3 ). More recently, this group reported data from a larger phase II multicentre trial enrolling 33 patients with EBV-positive PTLD from 19 transplant centres who had not responded to conventional therapy and were given the best-HLA-matched 'off-the-shelf ' product.
7 Using this approach achieved overall response rates of 64% at 5 weeks, and 52% at 6 months. The best results were observed in patients who received donor T cells that were best-HLA matched with the recipient. The above results are supported by reports from other centres. Sun et al. 67 described two solid organ transplantation recipients who responded to allogeneic CTLs with regressions of PTLD (Table 3) . Complete responses were also achieved in four of five patients treated at the Memorial Sloan-Kettering Cancer Center who received third party EBV-CTL lines. 68 In the patient who did not respond, the infused line was selectively restricted by a class II HLA allele not shared with the transplant donor-derived PTLD, again illustrating the importance of matching activity in the infused line to antigens shared with tumour cells. We have also evaluated the use of third-party multivirus-specific CTLs to treat patients with refractory viral infections in a multi centre study that included five patients with EBV-associated PTLD.
6, 69, 70 Although two of these five patients did not respond, the other three obtained a partial or complete response.
Interpretation of these results is not straight forward because many of the patients who responded also had their immunosuppressive treatments reduced and received other therapies. 7, 70 Hence, the encouraging bene fits cannot be solely ascribed to the allogeneic CTLs. T-cell persistence was also reduced compared with donor-derived cells, and in some instances multiple infusions were required to control PTLD. 6 Nevertheless, this approach has shown considerable promise, warranting further testing in definitive studies. If CTL banks are to succeed, it will be important to establish criteria that would provide broad coverage. There are potential advantages to using homozygous donors that facilitate characterization of antigen-specificity and HLA restriction. With respect to the use of third-party cells, clinical protocols should allow for multiple infusions and for the substitution of donor lines if patients fail to respond.
We would recommend the use of directly selected T cells for recipients of related-donor HSCT, and the use of third-party, banked CTLs for HSCT recipients with unrelated donors, and for solid organ recipients. This choice would provide time for the generation of 'rapid CTLs' , from small amounts of donor cryo preserved blood at the time of transplant or from the solid organ recipients.
Making CTLs resistant to immunosupression
In the setting of solid organ transplantation, persistence of infused CTLs has been limited probably because these patients remain on long-term immune suppression. Similarly, CTLs would likely not persist after HSCT in patients on immune suppression owing to GvHD. Hence, CTLs have been genetically modified to render them resistant to cyclosporine or tacrolimus or rapamycin in preclinical studies, [71] [72] [73] although the efficiency of these strategies has not yet been evaluated in the clinic.
Conclusions
Cell-based immunotherapy with donor-derived lymphocytes or CTLs specific for EBV antigens has proved highly effective in treating PTLD in the HSCT setting. Current research is focused on broadening the application of this approach by optimizing manufacturing processes so that CTL products can be more rapidly available for infusion on a routine basis, and to provide broad spectrum anti-viral coverage. Third-party CTL infusions targeting EBV lymphomas have also shown promise, and HLA-matching requirements and the factors associated with response are being defined to optimize this strategy further. Of note, all of these T-cell therapies, except DLI, are currently experimental and only available in the context of clinical trials, although some approaches are being or will soon be tested in late phase or licen sing studies after HSCT. Table 4 summarizes the T-cell approaches under evaluation, and lists the advantages and disadvantages of each of them. It will also be important eventually to undertake cost effectiveness analyses of different types of T-cell therapies compared with other options such as rituximab. Overall, however, the impli cations of this work are that EBV-specific T cell therapy for PTLD can now move beyond a single centre 'boutique' approach and has the potential for mainstream use especially given the promise of the 'off the shelf ' third-party CTL product. Future therapeutic strategies for PTLD may therefore now focus on combination immune-based therapies with targeted T cell and antibody therapies. Hence, such an approach has the potential to minimize the use of untargeted cytotoxic chemotherapy for patients, even those with advancedstage disease, thereby potentially not only preventing unacceptable toxicities but also an improved outcome for patients with EBV-associated PTLD.
